Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2008

View Archived Issues

Recent Japanese patents describe new agents for endocrine-related disorders

Novel antiinfective agents disclosed in recent patent literature

New immmunosuppressants for preventing transplant rejection reported in recent Rigel patent

Hsp90 inhibitor MPC-3100 active in tumor models

PROTECT-1: 45% clinical remission rate with CCX-282-B in Crohn's disease patients

Parion and Kainos sign clinical development agreement for dry mouth treatment P-552

Allergan and Spectrum collaborate on apaziquone development

Phase I data on Millennium's Aurora A kinase inhibitors available

GlaxoSmithKline to acquire Genelabs Technologies

Radezolid and linezolid equally effective in uncomplicated skin and skin structure infections

DAC initiates phase I/IIa clinical trial of DAC-0060 in non-melanoma skin cancers

Lpath and Merck Serono sign worldwide license agreement for ASONEP monoclonal antibody

Alvine reports results from phase I clinical trial of ALV-003 in celiac disease

Nabi reports final results from phase II immunogenicity study of NicVAX

Snapshots: ACCESS, CHARM, CARE results for adalimumab in Crohn's disease

Preclinical data on D-3263 show anticancer potential of TrpM8 agonism

SuperGen reports on development of JAK2 inhibitor SGI-1252

Karo's phase II study expands the potential for eprotirome in dyslipidemia

Morria presents preliminary results from phase II allergic rhinitis study

Telik reports top-line results from Assist-5 trial in ovarian cancer

Infinity expands phase II study of IPI-504 in advanced non-small cell lung cancer

Takeda submits NDA for Actos combination tablet in Japan

FDA accepts for priority review ImClone and Bristol-Myers' sBLA for Erbitux

FDA grants orphan drug status to Aldagen's ALD-101 stem cell therapy

Patient enrollment complete in RES-ELUTION I trial of Cordis and Conor Medsytems' Nevo stent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...